Objective To study the protective effects of Ginkgo biloba injection on the renal in diabetic nephropathy rats. Methods The models of diabetic rats were induced by streptozotecin. SD rats (n=18) were randomly divided into three groups, including control group, diabetic group and treated group. After 6 weeks, blood glucose, serum cholesterol and urinary protein were measured respectively. The expression of MCP-1 in the glomerulus was determined by immunohistechemical staining. Results Xingding injection did not influence blood glucose and serum cholesterol, but significantly inhibited expression of MCP-1 and lowered urinary protein excretion. Conclusion Xingding injection has some protective effect, which may be through down-regulating MCP-1 expression.

Objective To investigate the expression and clinical significance of the long non-coding RNA MALAT-1 in epithelial ovarian cancer (EOC).Methods The expressions of MALAT-1 mRNA in 29 EOC tissues and 20 normal ovarian tissues were detected by real-time fluorescence quantitative PCR.The relationships between the expression of MALAT-1 mRNA in EOC and its clinical pathological characteristics were analyzed.Results The expression of MALAT-1 mRNA in EOC tissues was lower than that in normal ovarian tissues (0.089±0.090 vs 1.450±1.404,t =4.331,P ＜ 0.001).The expression of MALAT-1 mRNA in advanced (Ⅲ-Ⅳ) stage tissues was significantly lower than that in early (Ⅰ-Ⅱ) stage tissues (0.044±0.043 vs 0.174±0.095,t =-5.125,P ＜ 0.05).The expression of MALAT-1 mRNA was significantly lower in poorly differentiated and poorly-moderately differentiated ovarian cancer than that in well differentiated ones (0.070 ±0.091 vs 0.161±0.021,t =2.409,P =0.023).The expression of MALAT-1 mRNA was significantly lower in tissues with the lymphonode or omental metastasis than that in tissues without invasion (0.045±0.047 vs 0.142±0.102,t =3.378,P =0.002).Conclusions The expression of long non-coding RNA MALAT-1 is lower in EOC,which is related to tumor grade,clinical stage,lymphonode and omental metastasis.It is suggested that MALAT-1 may play an inhibition role in the progress of ovarian cancer.

Sixty two patients with small bowel bleeding underwent double balloon endoscopy (DBE).Clinical features were compared between patients with positive DBE findings (50 cases) and those with negative findings (12 cases).Results revealed that the causes of melena were discovered in 75.0％(21/28) patients via oral approach,while the lesions were found in 81.8％ (18/22) patients with hematochezia via anal approach ( P ＜ 0.01 ). Duration of bleeding was longer and number of bleeding episodes was higher in patients with positive DBE findings than those with negative findings (P ＜ 0.05 or P ＜ 0.01 ).The time interval between the latest bleeding and DBE was significantly shorter in patients with positive DBE findings (P ＜ 0.05).Positive diagnostic rate was significantly higher in patients with three or more bleeding episodes than those less than three times (92.5％ vs.11.1％,P ＜ 0.01 ).DBE performed within seven days or less increased the positive diagnostic rate significantly than that after seven days (97.1％ vs.59.3％,P＜0.01).

Objective To investigate the efficacy and safety of leflunomide as induction and mainten-ance therapy for class Ⅴ lupus nephritis. Methods Sixteen patients with lupus nephritis (of which, three proven with Ⅴ +Ⅲ, six with Ⅴ+Ⅳ ), proven by renal biopsies, were included in this study. ALL patients rec-eived LEF plus prednisone treatment. For induction therapy, all patients were given an initial loading dose of LEF 60 mg daily for three days, followed by 20 mg daily for the whole induction treatment period. Prednisone was given starting from 0.8 mg per kilogram daily, then tapered four weeks later. After twenty-four weeks, the dosages of LEF and prednisone were 10 mg/d, 5～10 mg/d respectively during maintenance therapy. We asses-sed total remission rates in the end of twenty-four weeks, as well as the changes of system lupus erythematosus disease activity index (SLEDAI), urinary protein per twenty-four hours (24 h Upr), serum albumin, serum creatinine level, complement C3, complement C4, C reactive protein, serum titer of ANA and anti-dsDNA be-fore treatment, 12 weeks, 24 weeks and 48 weeks after treatment respectively. Meanwhile, seven patients received repeated renal biopsies after completing induction therapy, so we compared pathological activity index (AI) and chroniciry index (CI) between pre-therapy and post-therapy at the same time. T and t' test were selected. Results Sixteen patients were followed-up. After 24 weeks induction therapy, the total remission rate was 75.0%; SLEDAI was significantly lower than pre-therapy [(15.4±3.5) vs (6.9±1.7), P<0.05]; 24 h Upr was also significantly lower than pre-therapy [(5.8±2.2) g vs (l.3±0.5) g, P<0.01 ]. Unfortunately, all seven patients performed repeated renal biopsies with class Ⅴ lupus nephritis again histologically, of which two were transformed other cater-ofies. Comparing with that of pre-therapy, AI was improved after therapy [(2.4±0.9) vs (1.7±0.8), P<0.05]. However, CI indicated no difference. Adverse events including major infection occurred in four patients. The adverse events happened at the 12 th week after treatment. Conclusion The efficacy of LEF plus corticoster-oids as induction and maintenance therapy for class Ⅴ lupus nephritis is remarkable and the tolerance of patients is good.